Ascendis Pharma, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on the stock and has a $288.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tazeen Ahmad has given his Buy rating due to a combination of factors, including resilient demand for Yorvipath despite first-quarter seasonality and temporary reimbursement issues that weighed on reported revenue. Management indicated that these headwinds have already normalized, and they anticipate a solid rebound in the second quarter, supported by robust new prescriptions, expanding prescriber adoption, and improving market access metrics.
Ahmad also highlights the early but encouraging U.S. launch signals for Yuviwel and the company’s expectation of meaningful operating cash flow generation from its three rare endocrine products by 2026. Although Skytrofa modestly undershot expectations due to inventory dynamics, guidance for stable sales and a progressing pipeline—such as upcoming TransCon CNP data and advancement into late-stage trials—support a constructive long-term outlook, even as the price objective is modestly trimmed to $288 to reflect a higher share count.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $325.00 price target.